Summary Company Announcement Date: November 08, 2019 FDA Publish Date: November 08, 2019 Product Type: Drugs Reason for Announcement: Recall Reason Description NDMA (Nitrosodimethylamine) impurity Company […]
For Immediate Release: August 05, 2022 Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable […]
Product: Drugs Recipient: Recipient Name Arend John Kuijvenhoven FluxxLab LLC 1681 Niagara Rd.Montrose, CO 81401United States [email protected] WARNING LETTER RE: 637158 Date: August 4, 2022 TO: Arend […]
Summary Company Announcement Date: August 04, 2022 FDA Publish Date: August 04, 2022 Product Type: Drugs Reason for Announcement: Recall Reason Description Microbial contamination with Gluconacetobacter […]
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.